<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889056</url>
  </required_header>
  <id_info>
    <org_study_id>EPOPERF CH12</org_study_id>
    <nct_id>NCT01889056</nct_id>
  </id_info>
  <brief_title>Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      The blood hormone Erythropoietin (Epo) is not only produced by the kidneys but also by the&#xD;
      brain, especially under hypoxic conditions. It has been shown in animal studies and human&#xD;
      studies that Epo has neuroprotective properties. Furthermore, there is scientific evidence&#xD;
      for central modulatory effects of Epo in the brain but high dose of Epo is needed to overcome&#xD;
      the blood brain barrier. In a double blind placebo controlled crossover study we will&#xD;
      investigate the effects of a single high dose of Epo on cognitive function and exercise&#xD;
      capacity in healthy subjects. The subjects will receive a single high dose of Epo (60.000 IU)&#xD;
      and will perform a computerized cognitive test battery, a breathing test, a maximal exercise&#xD;
      capacity test (VO2max), and a time trial (TT) 24 hours after the treatment. The primary&#xD;
      outcome of the study will be the cognitive function.&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>1 year</time_frame>
    <description>The following parameters of cognitive function will be tested via computer-based cognitive testing (Units: Scores, Percent Correct, Response time):&#xD;
Working memory capacity&#xD;
Executive function&#xD;
Processing speed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of exercise capacity via specific exercise tests:&#xD;
VO2max test&#xD;
20-minutes time trial (TT)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjective Well-Being</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of subjective well-being via:&#xD;
Questionnaires&#xD;
Visual Analog Scales</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Erythropoietin (Epoetin beta)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short infusion of 60.000 IU Epoetin beta in 0.9% sodium chloride solution (250 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% sodium chloride solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Short infusion of 0.9% sodium chloride solution (250 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin (Epoetin beta)</intervention_name>
    <arm_group_label>Erythropoietin (Epoetin beta)</arm_group_label>
    <other_name>Recormon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride solution</description>
    <arm_group_label>0.9% sodium chloride solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy Subjects;&#xD;
&#xD;
          -  Age between 18 to 35 years;&#xD;
&#xD;
          -  Normal body weight (body mass index of &gt;= 18.5 kg/m2 &lt;= 24.9 kg/m2);&#xD;
&#xD;
          -  Nonsmokers (&gt;= 1 year);&#xD;
&#xD;
          -  VO2max of &lt;= 55 ml/kg/min for females and &lt;= 60 ml/kg/min for males;&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Persons with abnormal Serum Ferritin levels according to gender dependent reference&#xD;
             values of GCP-certificated laboratory;&#xD;
&#xD;
          -  Persons with pre-existing genetic hemostatic disorders (Factor V Leiden mutation,&#xD;
             Prothrombin mutation);&#xD;
&#xD;
          -  Persons which are at risk of deep venous thrombosis (e.g. history of venous&#xD;
             thromboembolic events);&#xD;
&#xD;
          -  Persons with a hematocrit value of &gt; 55%;&#xD;
&#xD;
          -  Persons being exposed to prolonged (&gt;= 5 days) high altitude (&gt;= 2500m above Normal&#xD;
             Null) &lt;= 6 months prior the beginning of the study;&#xD;
&#xD;
          -  Persons not willing to maintain their living conditions during the study period (e.g.&#xD;
             preparing for a certain competition);&#xD;
&#xD;
          -  Contraindications to the class of drugs under study, e.g. known hypersensitivity or&#xD;
             allergy to class of drugs or the investigational product;&#xD;
&#xD;
          -  Pregnant or breast feeding women;&#xD;
&#xD;
          -  Intention to become pregnant during the course of the study;&#xD;
&#xD;
          -  Lack of safe contraception;&#xD;
&#xD;
          -  Treatment with other investigational products;&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse;&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders;&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study;&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Maggiorini, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Medical intensive care unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Medical intensive care unit</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>Cognition</keyword>
  <keyword>Exercise</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

